Boston Heart Diagnostics, part of the Eurofins network of companies, announces the launch of LipidSeqTM, a revolutionary genetic test for cardiovascular disease. This saliva-based NGS test identifies the most common genetic causes of lipid and lipoprotein disorders. These disorders are associated with premature cardiovascular, pancreatic, kidney, and neurological diseases.

Read the full press release here:
Download Press Release